(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid (Compound)
Analyze
The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View (4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid's neighborhood in the knowledge graph.
The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for (4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid.
The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with (4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid.
Results found
Linked to
(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid bioactivity Somatostatin receptor type 3
Knowledge Graph Assertion (Entity type)A Knowledge Graph Assertion from IDG
(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid bioactivity Somatostatin receptor type 1
Knowledge Graph Assertion (Entity type)A Knowledge Graph Assertion from IDG
(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid bioactivity Somatostatin receptor type 5
Knowledge Graph Assertion (Entity type)A Knowledge Graph Assertion from IDG
(4R,7S,10R,13S,16R,19S,22R,25S,28R,31S)-16-((1H-indol-3-yl)methyl)-25-(2-amino-2-oxoethyl)-13,28-bis(4-aminobutyl)-31-(2-((S)-2-aminopropanamido)acetamido)-19,22-dibenzyl-10-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonaazacyclodotriacontane-4-carboxylic acid bioactivity Somatostatin receptor type 4
Knowledge Graph Assertion (Entity type)A Knowledge Graph Assertion from IDG